127 related articles for article (PubMed ID: 33197187)
1. Diazaspirononane Nonsaccharide Inhibitors of O-GlcNAcase (OGA) for the Treatment of Neurodegenerative Disorders.
Martínez-Viturro CM; Trabanco AA; Royes J; Fernández E; Tresadern G; Vega JA; Del Cerro A; Delgado F; García Molina A; Tovar F; Shaffer P; Ebneth A; Bretteville A; Mertens L; Somers M; Alonso JM; Bartolomé-Nebreda JM
J Med Chem; 2020 Nov; 63(22):14017-14044. PubMed ID: 33197187
[TBL] [Abstract][Full Text] [Related]
2. GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation.
Dorfmueller HC; Borodkin VS; Schimpl M; van Aalten DM
Biochem J; 2009 May; 420(2):221-7. PubMed ID: 19275764
[TBL] [Abstract][Full Text] [Related]
3. MK-8719, a Novel and Selective
Wang X; Li W; Marcus J; Pearson M; Song L; Smith K; Terracina G; Lee J; Hong KK; Lu SX; Hyde L; Chen SC; Kinsley D; Melchor JP; Rubins DJ; Meng X; Hostetler E; Sur C; Zhang L; Schachter JB; Hess JF; Selnick HG; Vocadlo DJ; McEachern EJ; Uslaner JM; Duffy JL; Smith SM
J Pharmacol Exp Ther; 2020 Aug; 374(2):252-263. PubMed ID: 32493725
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice.
Hastings NB; Wang X; Song L; Butts BD; Grotz D; Hargreaves R; Fred Hess J; Hong KK; Huang CR; Hyde L; Laverty M; Lee J; Levitan D; Lu SX; Maguire M; Mahadomrongkul V; McEachern EJ; Ouyang X; Rosahl TW; Selnick H; Stanton M; Terracina G; Vocadlo DJ; Wang G; Duffy JL; Parker EM; Zhang L
Mol Neurodegener; 2017 May; 12(1):39. PubMed ID: 28521765
[TBL] [Abstract][Full Text] [Related]
5. Novel glucopyranoside C2-derived 1,2,3-triazoles displaying selective inhibition of O-GlcNAcase (OGA).
Igual MO; Nunes PSG; da Costa RM; Mantoani SP; Tostes RC; Carvalho I
Carbohydr Res; 2019 Jan; 471():43-55. PubMed ID: 30412832
[TBL] [Abstract][Full Text] [Related]
6. Distinctive inhibition of O-GlcNAcase isoforms by an alpha-GlcNAc thiolsulfonate.
Kim EJ; Amorelli B; Abdo M; Thomas CJ; Love DC; Knapp S; Hanover JA
J Am Chem Soc; 2007 Dec; 129(48):14854-5. PubMed ID: 17994748
[TBL] [Abstract][Full Text] [Related]
7. O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer's disease and related tauopathies: analysis of the patent literature.
Bartolomé-Nebreda JM; Trabanco AA; Velter AI; Buijnsters P
Expert Opin Ther Pat; 2021 Dec; 31(12):1117-1154. PubMed ID: 34176417
[No Abstract] [Full Text] [Related]
8. Elevation of cellular O-GlcNAcylation level by a potent and selective O-GlcNAcase inhibitor based on tetrahydroimidazopyridine scaffold.
Li T; Li Z; Li J; Wang J; Guo L; Wang PG; Zhao W
Bioorg Med Chem Lett; 2012 Nov; 22(22):6854-7. PubMed ID: 23058883
[TBL] [Abstract][Full Text] [Related]
9. Thiamme2-G, a Novel O-GlcNAcase Inhibitor, Reduces Tau Hyperphosphorylation and Rescues Cognitive Impairment in Mice.
Pan D; Gu JH; Zhang J; Hu Y; Liu F; Iqbal K; Cekic N; Vocadlo DJ; Dai CL; Gong CX
J Alzheimers Dis; 2021; 81(1):273-286. PubMed ID: 33814439
[TBL] [Abstract][Full Text] [Related]
10. Structure-based discovery and development of novel O-GlcNAcase inhibitors for the treatment of Alzheimer's disease.
Li X; Han J; Bujaranipalli S; He J; Kim EY; Kim H; Im JH; Cho WJ
Eur J Med Chem; 2022 Aug; 238():114444. PubMed ID: 35588599
[TBL] [Abstract][Full Text] [Related]
11. A Convenient Approach to Stereoisomeric Iminocyclitols: Generation of Potent Brain-Permeable OGA Inhibitors.
Bergeron-Brlek M; Goodwin-Tindall J; Cekic N; Roth C; Zandberg WF; Shan X; Varghese V; Chan S; Davies GJ; Vocadlo DJ; Britton R
Angew Chem Int Ed Engl; 2015 Dec; 54(51):15429-33. PubMed ID: 26545827
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a Novel and Brain-Penetrant
Tawada M; Fushimi M; Masuda K; Sun H; Uchiyama N; Kosugi Y; Lane W; Tjhen R; Endo S; Koike T
J Med Chem; 2021 Jan; 64(2):1103-1115. PubMed ID: 33404239
[No Abstract] [Full Text] [Related]
13. Defining the structural origin of the substrate sequence independence of O-GlcNAcase using a combination of molecular docking and dynamics simulation.
Martin JC; Fadda E; Ito K; Woods RJ
Glycobiology; 2014 Jan; 24(1):85-96. PubMed ID: 24134879
[TBL] [Abstract][Full Text] [Related]
14. Screening-based discovery of drug-like O-GlcNAcase inhibitor scaffolds.
Dorfmueller HC; van Aalten DM
FEBS Lett; 2010 Feb; 584(4):694-700. PubMed ID: 20026047
[TBL] [Abstract][Full Text] [Related]
15. O-GlcNAcase overexpression reverses coronary endothelial cell dysfunction in type 1 diabetic mice.
Makino A; Dai A; Han Y; Youssef KD; Wang W; Donthamsetty R; Scott BT; Wang H; Dillmann WH
Am J Physiol Cell Physiol; 2015 Nov; 309(9):C593-9. PubMed ID: 26269457
[TBL] [Abstract][Full Text] [Related]
16. Structural insights into the substrate binding adaptability and specificity of human O-GlcNAcase.
Li B; Li H; Hu CW; Jiang J
Nat Commun; 2017 Sep; 8(1):666. PubMed ID: 28939839
[TBL] [Abstract][Full Text] [Related]
17. O-GlcNAcase: promiscuous hexosaminidase or key regulator of O-GlcNAc signaling?
Alonso J; Schimpl M; van Aalten DM
J Biol Chem; 2014 Dec; 289(50):34433-9. PubMed ID: 25336650
[TBL] [Abstract][Full Text] [Related]
18. Evidence of a compensatory regulation of colonic O-GlcNAc transferase and O-GlcNAcase expression in response to disruption of O-GlcNAc homeostasis.
Decourcelle A; Loison I; Baldini S; Leprince D; Dehennaut V
Biochem Biophys Res Commun; 2020 Jan; 521(1):125-130. PubMed ID: 31630803
[TBL] [Abstract][Full Text] [Related]
19. O-GlcNAcase deficiency suppresses skeletal myogenesis and insulin sensitivity in mice through the modulation of mitochondrial homeostasis.
Wang X; Feng Z; Wang X; Yang L; Han S; Cao K; Xu J; Zhao L; Zhang Y; Liu J
Diabetologia; 2016 Jun; 59(6):1287-96. PubMed ID: 26993634
[TBL] [Abstract][Full Text] [Related]
20. Ac
Wang H; Guo J; Wang N; Wang J; Xue Q; Wang J; Liu W; Liu K; Cao X; Zhao W; Xi R; Niu Y; Wang P; Li J
Bioorg Med Chem Lett; 2019 Mar; 29(6):802-805. PubMed ID: 30713024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
